Company Overview
Company Type: Public Company
Website: www.eupraxiapharma.com
Number of Employees: 21
Ticker: EPRX (TSX)
Year Founded: 2011


Business Description
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company’s lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
190.8
EBITDA
(26.0)
Total Enterprise Value
181.1
TEV/EBITDA
NM
EBIT
(26.1)
Cash & ST Invst.
19.1
P/Diluted EPS Before Extra
NM
Net Income
(26.3)
Total Debt
11.1
Price/Tang BV
22.4x
Capital Expenditure
(0.2)
Total Assets
20.4
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
(0.32)
(0.60)
(1.44)
(2.02)
(1.73)
Revenue (mm)
0.00
0.00
0.00
0.00
0.00
EBITDA (mm)
-
-
(30.00)
(30.00)
(30.00)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/EBITDA
NM
P/BV
NM

Non-Periodic Estimates

Recommendation
Buy (1.00)
Target Price
15.08
Potential Upside
116.71%


Key Professionals
Name
Title
Helliwell, James A.
CEO & Director
Cousins, Bruce G.
President & CFO
Malone, Amanda 
Chief Scientific Officer
Brennan, Paul Anthony
Chief Business Officer
Kowalski, Mark M.
Chief Medical Officer

Key Board Members
Name
Title
Pimstone, Simon N.
Independent Chairman
Helliwell, James A.
CEO & Director
Glickman, Richard M.
Independent Director
Montalbano, John Salvatore
Independent Director
Geyer, Paul L.
Independent Director
Wilmink, Michael 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
2067 Cadboro Bay Road Suite 201 | Victoria, BC | V8R 5G4 | Canada
Phone: 250-590-3968   

Current and Pending Investors
Manchester Management Company, LLC, Silicon Valley BancVentures, Inc., Stadnyk and Partners Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 6.96
Market Cap (mm)
189.8
Open
 7.04
Shares Out. (mm)
27.3
Previous Close
 6.96
Float %
68.2%
Change on Day
(0.04)
Shares Sold Short (mm)
-
Change % on Day
(0.6)%
Dividend Yield %
-
Day High/Low
 7.06/ 6.85
Diluted EPS Excl. Extra Items
(1.21)
52 wk High/Low
 9.10/ 2.30
P/Diluted EPS Before Extra
NM
Volume (mm)
0.02
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
1.32


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
TSX:EPRX - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
AMDM Holdings Inc.
AMDM Holdings Inc. was incorporated in 2016 and is based in Victoria, Canada. The company operates as a subsidiary of Eupraxia Pharmaceuticals Inc.

United States and Canada
-
-
-
-
Eupraxia Pharmaceuticals USA, LLC

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-04-2023
Aug-18-2023
Private Placement
Target
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)


16.45
Jun-15-2023
-
Shelf Registration
Target
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)


200.00
Apr-20-2022
Apr-20-2022
Private Placement
Target
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Manchester Management Company, LLC

-
Apr-11-2022
Apr-20-2022
Public Offering
Target
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)


10.49
Dec-13-2021
-
Shelf Registration
Target
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)


22.78
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-11-2023
Company Conference Presentations
Eupraxia Pharmaceuticals Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-11-2023
Sep-08-2023
Company Conference Presentations
Eupraxia Pharmaceuticals Inc. Presents at PAINWeek Conference 2023, Sep-08-2023 07:30 AM
Sep-07-2023
Auditor Changes
Eupraxia Pharmaceuticals Inc. Announces Auditor Changes
Aug-18-2023
Private Placements
Eupraxia Pharmaceuticals Inc. announced that it has received CAD 22.287125 million in funding
Aug-04-2023
Private Placements
Eupraxia Pharmaceuticals Inc. announced that it expects to receive CAD 21.999999 million in funding


Advisors
Most Recent Auditor
Wolrige Mahon Collins Barrow LLP
Public Offering Advisors
Baker Tilly WM LLP, Blake, Cassels & Graydon LLP


Most Recent Auditor
Baker Tilly WM LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

04:28 AM
EPRX
Eupraxia Pharmaceuticals Inc 2023_10_05
Reports
14
CFRA Equity Research

Oct 01, 2023 12:23 PM
EPRX
Eupraxia Pharmaceuticals Inc.
Reports
9
Raymond James Ltd.
Sarugaser, Rahul
Sep 25, 2023 04:56 AM
EPRX
EPRX | ↑$18 | EoE Takes Front Seat: Now Lead Clin. Prog. | 2H23 Ph2 EoE Data Derisked by Ph2 OA Data
EPS Estimates*
11
GlobalData

Sep 15, 2023 01:26 AM
EPRX
Eupraxia Pharmaceuticals Inc (EPRX.TSE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
38
GlobalData

Sep 11, 2023 03:43 AM
EPRX
Eupraxia Pharmaceuticals Inc (EPRX.TSE) - Financial Analysis Review
Reports
84
S&P Global Compustat

Sep 07, 2023 04:27 AM
EPRX
Eupraxia Pharmaceuticals Inc 2023_09_07
Reports
14
Research Capital Corporation
Uddin, Andre
Aug 25, 2023 06:15 AM
EPRX
Q2 - Revised Estimates & Cashing Up to Initiate the Next Phase - Trimming TP
Initiation of Coverage*
5
Canaccord Genuity
Armstrong-Whitworth, Tania Rae
Aug 20, 2023 04:02 PM
EPRX
Q2/23: Re-capitalized in advance of Phase 3
Reports
7
GlobalData

Aug 18, 2023 04:51 AM
EPRX
Eupraxia Pharmaceuticals Inc (EPRX.TSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
40
S&P Global Compustat

Jul 06, 2023 03:47 AM
EPRX
Eupraxia Pharmaceuticals Inc 2023_07_06
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Manchester Management Company, LLC

5,445,171

19.97

38.5

May-10-2022


Montalbano C.F.A., CFA, John Salvatore

1,197,666

4.39

8.5

Aug-18-2023


Pathfinder Asset Management Limited

1,106,500

4.06

7.8

Dec-31-2022


Helliwell FRCPC, M.D., James A.

674,012

2.47

4.8

Aug-18-2023


Geyer B.A.Sc., P.Eng, P.Eng., Paul L.

340,346

1.25

2.4

Aug-18-2023


Johnson, Douglas B.

277,500

1.02

2.0

Dec-31-2022


Wilmink FRCSC, M.D., Michael 

219,425

0.80

1.6

Aug-18-2023


Frank, Morgan C.

153,659

0.56

1.1

Apr-20-2022


Besser, James E.

138,293

0.51

1.0

Apr-20-2022


Cousins CPA, C.A., CPA, Bruce G.

114,286

0.42

0.8

Aug-18-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Montalbano C.F.A., CFA, John Salvatore
1,197,666
75,000
Cousins CPA, C.A., CPA, Bruce G.
114,286
14,286
Helliwell FRCPC, M.D., James A.
674,012
14,286
Kowalski M.D., Ph.D., Mark M.
8,000
8,000
Malone Ph.D., Amanda 
46,343
7,143

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
EP-104IAR (Future), EP-105 (Future), EP-201 (Future)


Upcoming Events
Date/Time
Type
Nov-08-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-11-2023
-
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
SEDAR
News Releases
141 KB
Sep-08-2023
-
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
SEDAR
Material Change Report
6 KB
Sep-07-2023
-
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
SEDAR
News Releases
204 KB
Sep-07-2023
-
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
SEDAR
Change of Auditor
51 KB
Sep-07-2023
-
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
SEDAR
Change of Auditor
78 KB
Sep-07-2023
-
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
SEDAR
Change of Auditor
13 KB
Sep-06-2023
-
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
SEDAR
News Releases
153 KB
Aug-23-2023
-
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
SEDAR
Material Change Report
68 KB
Aug-18-2023
-
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
SEDAR
News Releases
207 KB
Aug-11-2023
Jun-30-2023
Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
SEDAR
Interim Financial Statements
1016 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Pimstone FRCPC, M.B. ChB., M.D., Ph.D., Simon N. (Independent Chairman)
Aug-18-2023
Common Shares
4,000
28,382
Private Acquisition
86.47
Multiple
Glickman L.L.D. (Hon), Richard M. (Independent Director)
Aug-18-2023
Common Shares
1,430
10,147
Private Acquisition
11.44
Multiple
Geyer B.A.Sc., P.Eng, P.Eng., Paul L. (Independent Director)
Aug-18-2023
Common Shares
3,600
25,544
Private Acquisition
1.07
Multiple
Brennan B.Sc., M.Sc., Paul Anthony (Chief Business Officer)
Aug-18-2023
Common Shares
5,000
35,478
Private Acquisition
22.52
Multiple
Cousins CPA, C.A., CPA, Bruce G. (President & CFO)
Aug-18-2023
Common Shares
14,286
101,367
Private Acquisition
14.29
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Pimstone, Simon N.
Independent Chairman
250-590-3968
-
spimstone@xenon-pharma.com
Helliwell, James A.
CEO & Director
250-590-3968
-

Glickman, Richard M.
Independent Director
250-590-3968
-

Montalbano, John Salvatore
Independent Director
250-590-3968
-

Geyer, Paul L.
Independent Director
250-590-3968
-

Wilmink, Michael 
Independent Director
250-590-3968
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Helliwell, James A.
CEO & Director
250-590-3968
-

Cousins, Bruce G.
President & CFO
250-590-3968
-

Malone, Amanda 
Chief Scientific Officer
250-590-3968
-

Brennan, Paul Anthony
Chief Business Officer
250-590-3968
-

Kowalski, Mark M.
Chief Medical Officer
250-590-3968
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
